ALLO — Allogene Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1737287 ·
Last close
$0.74
Market Cap
$257.08M
52W High
$4.46
52W Low
$0.74
ADV30
9,919,924
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -54,793,000 -50,369,000 511,320,000 29,270,000 118,768,000
Jun 2026 4,640,000 — -46,920,000 -42,677,000 550,091,000 38,626,000 113,916,000
Mar 2026 0 — -46,092,000 -42,607,000 395,958,000 30,309,000 117,083,000
Dec 2025 0 — -42,404,000 -38,810,000 415,905,000 51,688,000 123,363,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-102,196,000
Investing CF
$-131,599,000
Financing CF
$220,089,000
CapEx
$-446,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.67
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,095,993,000
Inventory
—
Receivables
—
ST Investments
$293,978,000
EBIT TTM
$-164,194,000
Pretax Income TTM
$-165,494,000
Interest Exp TTM
$1,300,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,640,000
EBITDA
$-179,216,992
Free Cash Flow
$-63,461,624
Enterprise Value
$361,378,784
Total Cash
$332,604,000
Total Debt
$79,009,000
Shares Out
345,490,881
Trailing EPS
$-0.61
Book Value
$1.27
ROE
-42.4%
ROA
-22.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -206,933,000 -190,886,000 415,905,000 123,363,000 292,542,000 -149,246,000
Dec 2024 22,000 -257,482,000 -257,590,000 548,710,000 126,531,000 422,179,000 -200,300,000
Dec 2023 95,000 -314,492,000 -327,265,000 642,837,000 130,604,000 512,233,000 -237,733,000
Dec 2022 156,000 -335,536,000 -340,414,000 821,579,000 154,697,000 666,882,000 -220,519,000

TTM Snapshot

Revenues TTM
$4,640,000
NetIncome TTM
$-165,494,000
OpCashFlow TTM
—
Assets (Latest)
$550,091,000
Forward EPS
$-0.62

Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.00 · spot: $0.70 · call volume: 12 · put volume: 100

Peers — same industry

TickerNameMarket CapLastDaily %
OCGN Ocugen, Inc. $256.75M $0.76 —
IPSC Century Therapeutics, Inc. $248.79M $1.37 —
SABS SAB Biotherapeutics, Inc. $265.76M $2.95 —
PLX Protalix BioTherapeutics, Inc. $242.84M $2.88 —
TRXB TRex Bio, Inc. $274.46M $10.00 —

News headlines (Yahoo Finance, 1h cache)

Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
2026-11-09 13:00 · Yahoo
Allogene (ALLO) Q3 2026 Earnings Call Transcript
2026-11-06 15:32 · Yahoo
Allogene Therapeutics Inc (ALLO) (Q3 2026) Earnings Call Highlights: Alpha 3 Momentum Builds as ...
2026-11-06 07:19 · Yahoo
Allogene Therapeutics Q3 Earnings Call Highlights
2026-11-06 00:14 · Yahoo
Allogene Therapeutics: Q3 Earnings Snapshot
2026-11-05 21:33 · Yahoo
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
2026-11-05 21:02 · Yahoo
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
2026-11-03 13:00 · Yahoo
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
2026-10-29 12:30 · Yahoo
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
2026-10-26 12:30 · Yahoo
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
2026-09-02 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.